Press Release Distribution
Pricing
Customer Support
(800) 998-2927
Login
Log In
All Categories
Business
Entertainment
Health
Finance
Other
Tagged
505b2
Press Release
Nov 7, 2019
Bridge Therapeutics Announces It Will Seek FDA Approval for BT-219, a Treatment for Opioid Dependence in the Coming Months
Read More
Press Release
Oct 18, 2016
3rd Annual 505(b)(2) Forum to Discuss Product Development and Regulatory Updates
Read More
Press Release
Sep 27, 2016
Camargo Pharmaceutical Services Adds to Medical Device Expertise
Former FDA CDRH Medical Device Expert Joins Camargo
Read More
Press Release
Aug 10, 2016
Camargo Pharmaceutical Services Grows, Adds Three Drug Development Experts
Read More
Press Release
Jan 18, 2016
Camargo Pharmaceutical Services Integral in Medicines360's Intrauterine Contraceptive Device FDA Approval
Camargo Pharmaceutical Services, the most experienced global strategist in the drug development industry specializing in the 505(b)(2) approval pathway, has helped Medicines360 gain FDA approval for their hormonal intrauterine contraceptive device. This intrauterine contraceptive device is important because it is a high quality product which will reach underserved women in 340B family planning clinics, and is being made available to these clinics at an affordable price of $50.
Read More
First
Prev
1
Next
Last
